Immunotherapy in intermediate-risk biochemically recurrent prostate cancer (BCR): The National Cancer Institute experience.
A. B. Warner(National Institutes of Health), Ravi A. Madan(National Cancer Institute), William L. Dahut(National Cancer Institute), Susan F. Slovin(Cornell University), Amy Hankin(National Institutes of Health), Xiao X. Wei(Dana-Farber Cancer Institute), Lauren C. Harshman(Dana-Farber Cancer Institute), Choyke Pl(National Institutes of Health), Fatima Karzai(National Institutes of Health), Esther Mena(National Institutes of Health), Philip M. Arlen(Dana-Farber Cancer Institute), Jeanny B. Aragon-Ching(Virginia Cancer Institute), Monique Williams(National Institutes of Health), Jeffrey Schlom(National Institutes of Health), James L. Gulley(National Institutes of Health), M. Liza Lindenberg(National Institutes of Health), William D. Figg(National Institutes of Health), Renee N. Donahue(National Institutes of Health), Melissa L. Abel(National Institutes of Health)
Cited by 0
Related Papers
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975